Treatment with a CXC chemokine receptor type 4 (CXCR4) inhibitor, which has been suggested to block the CXCR4/CXCR12 axis involved in AML cells protection by stromal cells, was also tested [163,164]. This evidence concerns the gene CXCR4 and acute myeloid leukemia.